MetaCap

Precision BioSciences (DTIL) vs Kyverna Therapeutics (KYTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Precision BioSciences (DTIL) has outperformed Kyverna Therapeutics (KYTX) over the past year, gaining 48.0% versus a loss of 39.9%. Precision BioSciences is the larger company by market cap ($282.5 million vs $269.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DTIL+48.00%KYTX-39.92%
+120%+36%-48%
Nov 21, 20251 yearNov 20, 2026
DTIL-35.76%KYTX-85.85%
+30%-35%-100%
Feb 5, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DTIL versus KYTX key metrics
MetricDTILKYTX
Share price$7.40$4.26
Market cap$282.46M$269.33M
1-day change+7.09%-2.52%
YTD return+77.88%-54.68%
1-year return+48.00%-39.92%
5-year return-97.23%—
P/E ratio (TTM)29.60—
EPS (TTM)$0.25$-2.75
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$34.26M—
Revenue growth (YoY)-50.12%—
Net income (latest FY)$-45.72M$-161.31M
Operating margin-152.19%—
Net margin-133.45%—
52-week high$11.29$13.67
52-week low$3.53$4.18
Distance from 52-week high-34.46%-68.84%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+297.30%+613.62%
Average volume319.79K867.28K
Shares outstanding38.17M63.22M
Employees69172
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • DTIL has outperformed KYTX by 87.9 percentage points over the past year.

About Precision BioSciences

DTIL stock →

Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 69 employees

About Kyverna Therapeutics

KYTX stock →

Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 172 employees

DTIL vs KYTX FAQ

Which is bigger, Precision BioSciences or Kyverna Therapeutics?

Precision BioSciences (DTIL) is larger, with a market capitalization of $282.46M compared with $269.33M for Kyverna Therapeutics (KYTX).

Which stock has performed better over the past year, DTIL or KYTX?

DTIL returned +48.00% over the past 12 months, compared with -39.92% for KYTX (price return, excluding dividends). Past performance does not predict future results.

Are Precision BioSciences and Kyverna Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons